PIK3CA and ovarian serous adenocarcinoma: Notably, two responders in the dose escalation cohort had mutations in the MAPK or PI3K pathways, including one with KRAS-mutant CRC with neuroendocrine features and another with dual KRAS/PIK3CA-mutant low grade serous ovarian cancer.